RxDoctor Payments Data

Earl Potts, MD

Internal Medicine · N Dartmouth, MANPI 1679560791

Payments from drug & device makers

$117in general payments, 2019–2025

Across 6 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$53
  • Novo Nordisk$29
  • Lilly USA, LLC$20
  • Johnson & Johnson$14

What the payments were for

  • Food & beverage$117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie2$53
Novo Nordisk2$29
Lilly USA, LLC1$20
Johnson & Johnson1$14

How this compares

$117 in reported general payments places this provider in the 60th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$279,325
Medicare patients
379
Services billed
4,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$146,093
EliquisApixaban84$79,556
TrulicityDulaglutide39$49,876
JardianceEmpagliflozin36$48,291
JanuviaSitagliptin Phosphate29$33,650
XareltoRivaroxaban16$23,730
Advair HfaFluticasone Propion/Salmeterol31$19,060
Rosuvastatin Calcium436$17,595
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$15,650
Ezetimibe180$9,744
SymbicortBudesonide/Formoterol Fumarate24$9,458
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,018
Breo ElliptaFluticasone/Vilanterol16$7,620
Atorvastatin Calcium439$6,489
Pravastatin Sodium232$5,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$146,093109 claims
Lilly USA, LLCTrulicity$20$49,87639 claims
Johnson & JohnsonXarelto$14$23,73016 claims
AbbVieSynthroid$53$1,50919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in N Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →